Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.

Lin P, Luo Y, Zhu S, Maggio D, Yang H, Hu C, Wang J, Zhang H, Ren Y, Zhou X, Mei C, Ma L, Xu W, Ye L, Zhuang Z, Jin J, Tong H.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1037-1047. doi: 10.1007/s00432-018-2627-3. Epub 2018 Mar 16.

PMID:
29549529
2.

Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.

Jin J, Hu C, Yu M, Chen F, Ye L, Yin X, Zhuang Z, Tong H.

PLoS One. 2014 Jun 17;9(6):e100206. doi: 10.1371/journal.pone.0100206. eCollection 2014.

3.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C, Koscielny S, Scourzic L, Forget S, Pautas C, Caillot D, Preudhomme C, Dombret H, Berthon C, Barouki R, Rabier D, Auger N, Griscelli F, Chachaty E, Leclercq E, Courtier MH, Bennaceur-Griscelli A, Solary E, Bernard OA, Penard-Lacronique V, Ottolenghi C, de Botton S.

J Clin Oncol. 2014 Feb 1;32(4):297-305. doi: 10.1200/JCO.2013.50.2047. Epub 2013 Dec 16.

PMID:
24344214
4.

IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF, Xu WR.

Ann Hematol. 2012 Apr;91(4):519-25. doi: 10.1007/s00277-011-1352-7. Epub 2011 Oct 14.

PMID:
21997850
5.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Tong HY, Hu C, Yu MX, Ma QL, Chen FF, Ye L, Wei JY, Xu GX, Mao LP, Li Y, Jin J.

Zhonghua Yi Xue Za Zhi. 2013 Oct 29;93(40):3180-4. Chinese.

PMID:
24405536
6.

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.

Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Krämer A, Heilig CE.

Leukemia. 2016 Apr;30(4):782-8. doi: 10.1038/leu.2015.317. Epub 2015 Nov 19.

PMID:
26582645
7.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

8.

IDH mutations in cancer and progress toward development of targeted therapeutics.

Dang L, Yen K, Attar EC.

Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Review.

PMID:
27005468
9.

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY.

Haematologica. 2014 Jan;99(1):28-36. doi: 10.3324/haematol.2013.091249. Epub 2013 Aug 30.

10.

IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.

Wang N, Wang F, Shan N, Sui X, Xu H.

Acta Haematol. 2017;138(3):143-151. doi: 10.1159/000479546. Epub 2017 Sep 6.

11.

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A.

Leukemia. 2012 Jan;26(1):101-5. doi: 10.1038/leu.2011.298. Epub 2011 Oct 28.

PMID:
22033490
12.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M.

Blood. 2013 Jun 13;121(24):4917-24. doi: 10.1182/blood-2013-03-493197. Epub 2013 May 2.

13.

IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.

Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, Chen CY, Lai YJ, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Wu SJ, Tsay W, Chen YC, Tien HF.

Am J Hematol. 2014 Feb;89(2):137-44. doi: 10.1002/ajh.23596. Epub 2013 Nov 20.

14.

Isocitrate dehydrogenase mutations in myeloid malignancies.

Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R.

Leukemia. 2017 Feb;31(2):272-281. doi: 10.1038/leu.2016.275. Epub 2016 Oct 10. Review.

15.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW.

J Exp Med. 2010 Feb 15;207(2):339-44. doi: 10.1084/jem.20092506. Epub 2010 Feb 8.

16.

Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.

Chotirat S, Thongnoppakhun W, Wanachiwanawin W, Auewarakul CU.

Blood Cells Mol Dis. 2015 Mar;54(3):286-91. doi: 10.1016/j.bcmd.2014.11.017. Epub 2014 Nov 26.

PMID:
25486927
17.

[Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].

Zhu C, Ma Y, Xu XP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):873-8. doi: 10.7534/j.issn.1009-2137.2014.03.057. Review. Chinese.

PMID:
24989313
18.

Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.

Wang JH, Chen WL, Li JM, Wu SF, Chen TL, Zhu YM, Zhang WN, Li Y, Qiu YP, Zhao AH, Mi JQ, Jin J, Wang YG, Ma QL, Huang H, Wu DP, Wang QR, Li Y, Yan XJ, Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Jia W, Shen Y, Chen Z, Chen SJ.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17017-22. doi: 10.1073/pnas.1315558110. Epub 2013 Sep 30.

19.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

20.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020

Supplemental Content

Support Center